Kiniksa Pharmaceuticals International, plc KNSA Noncash Lease Expense
Noncash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept knsa:NoncashLeaseExpense.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's noncash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's noncash lease expense?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported noncash lease expense of $994K in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's noncash lease expense changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's noncash lease expense increased by 19.0% year-over-year, from $835K to $994K.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's noncash lease expense?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's noncash lease expense has grown at a 8.6% compound annual growth rate (CAGR), from $2.63M to $3.67M.
- What does noncash lease expense mean?
- This metric represents the portion of lease expenses recognized in the income statement that does not involve an immediate cash outflow. It reflects the systematic allocation of the right-of-use asset cost over the lease term, serving as a non-cash adjustment to reconcile net income to operating cash flow. Investors use this to isolate the impact of lease accounting standards on reported profitability versus actual cash obligations.